|Dr. Stefan Oschmann||Chairman of Exec. Board & CEO||6.55M||N/A||1957|
|Dr. Marcus Kuhnert||CFO & Member of Exec. Board||3.55M||N/A||1968|
|Dr. Kai Beckmann||CEO of Performance Materials & Member of the Exec. Board||3.88M||N/A||1965|
|Dr. Udit Batra||CEO of Life Science & Member of Exec. Board||4.24M||N/A||1971|
|Ms. Belén Garijo López M.D.||CEO of Healthcare & Member of the Exec. Board||5.46M||N/A||1960|
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc.; a collaboration with Daiichi Sankyo Company, Limited and BioMed X Innovation Center; a co-development agreement with Oncolytics Biotech Inc.; a partnership with GlucoMe LTD; and collaboration agreements with Phosplatin Therapeutics LLC and Vyriad Inc. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
MERCK Kommanditgesellschaft auf Aktien’s ISS governance QualityScore as of 3 February 2020 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 9; Compensation: 8.